Bioventus Inc. (BVS)

NASDAQ: BVS · USD

$14.6

+0.19 (+1.3%)· Recorded snapshot

Market cap	1.2B
Revenue (ttm)	581.8M
Net income (ttm)	54.5M
EPS (ttm)	$0.78
Shares out	84.1M
P/E (trailing)	18.7x
P/E (forward)	18.2x
Volume	507,264
Beta	0.64

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 581.8M
Net income (ttm): 54.5M
EPS (ttm): $0.78
P/E (trailing): 18.7x
P/E (forward): 18.2x
Market cap: 1.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E18.2

P25 13.4P50 20.2P75 35.7

Trailing P/E18.7

P25 15.4P50 25.8P75 43.5

ROE25.7

P25 -113.8P50 -46.5P75 -0.9

ROIC12.2

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All BVS indicators

Market & fundamental data

Available fields

258

Groups with data

Currency

USD

Showing 258 of 258 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001665988
Company name	Bioventus Inc.
Country	United States
Country code	US
CUSIP number	09075A108
Earnings date	2026-11-02
Earnings time	amc
Employees	950
Employees change	0
Employees growth	0%
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-27
First seen	2026-05-09
Fiscal year end	December
Founded	2011
In index	RUSSELL2000
Industry	Medical Devices
IPO date	2021-02-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US09075A1088
Last 10-K release date	2026-03-05
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.2B
Market cap category	Small-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$14.61
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	BVS
U.S. state	North Carolina
Website	https://www.bioventus.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	19.22x
Earnings yield	5.35%
EV/Earnings	26.67x
EV/EBIT	23.97x
EV/EBITDA	18.13x
EV/FCF	15.41x
EV/Sales	2.5x
FCF / EV yield	6.49%
FCF yield	7.73%
Forward EV/Sales	2.33x
Forward P/E	18.19x
Forward P/S	1.96x
Graham number	7.67471
Graham upside	-47.07%
Industry forward P/E	19.81x
Industry P/E	39.5x
Lynch fair value	$19.55
Lynch upside	34.85%
P/(FCF - SBC) ratio	15.36x
P/(OCF - SBC) ratio	14.88x
P/B ratio	4.31x
P/E ratio	18.68x
P/FCF ratio	12.93x
P/OCF ratio	12.59x
P/S ratio	2.1x
PEG ratio	1.64x
Price/EBITDA ratio	15.21x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	10.42%
EBITDA margin	13.77%
FCF margin	16.2%
Gross margin	68.65%
Operating margin	10.42%
Pretax margin	6.64%
Profit margin	9.36%
Profit per employee	$57,331
Profitable quarters	5
Profitable years	1
Revenue per employee	$612,472
ROA	5.49%
ROA (5Y)	1.59%
ROCE	11.64%
ROE	25.68%
ROE (5Y)	-15.09%
ROIC	12.15%
ROIC (5Y)	3.59%
SBC / revenue	2.56%
Tax / revenue	-3.92%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	327.28%
EPS growth (QoQ)	1,075%
EPS growth 5Y	24.66%
EPS growth quarters	2
EPS growth years	3
FCF growth	176.52%
FCF growth (Q)	-25.11%
FCF growth (QoQ)	126.23%
FCF growth 3Y	129.31%
FCF growth 5Y	18.77%
Gross profit growth	4.74%
Gross profit growth (Q)	3.5%
Gross profit growth 3Y	7.47%
Gross profit growth 5Y	8%
Net income growth (Q)	348.33%
Net income growth (QoQ)	974.24%
Net income growth 5Y	55.11%
Net income growth quarters	8
Net income growth years	3
OCF growth	167.27%
OCF growth (Q)	-23.38%
OCF growth (QoQ)	122.44%
OCF growth 3Y	75.81%
OCF growth 5Y	16.28%
Operating income growth	50.05%
Operating income growth (Q)	1.91%
Operating income growth 5Y	11%
Revenue growth	3.14%
Revenue growth (Q)	3.76%
Revenue growth (QoQ)	15.99%
Revenue growth 3Y	4.45%
Revenue growth 5Y	9.12%
Revenue growth quarters	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.6M
Depreciation and amortization	$19.5M
EBIT	$60.6M
EBITDA	$80.1M
EPS	$0.78
FCF per share	$1.12
Financing cash flow	$-95M
Free cash flow	$94.3M
Free cash flow minus SBC	$79.4M
Gross profit	$399.4M
Income taxes	$-22.8M
Investing cash flow	$-4.1M
Net borrowing	$-27.9M
Net cash flow	$-3.5M
Net income	$54.5M
Operating cash flow minus SBC	$82M
Operating income	$60.6M
Revenue	$581.8M
Stock-based compensation	$14.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.54
Book value per share	$3.35
Debt / EBITDA	3.08
Debt / equity	0.95
Debt / FCF	2.8
Goodwill	$7.5M
Interest coverage	3.05
Long-term assets	$415.8M
Long-term liabilities	$243.5M
Net cash (debt)	$-233.4M
Net cash / market cap	-19.14%
Net debt / EBITDA	2.91
Net debt / equity	0.84
Net debt / FCF	2.47
Piotroski F-Score	8
Property, plant and equipment	$24.8M
Shareholders' equity	$277.4M
Tangible book value	$-130.2M
Tangible book value per share	$-1.91
Total assets	$673.3M
Total cash	$30.4M
Total debt	$263.7M
Total liabilities	$395.9M
WACC	7.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.84
Current assets	$257.5M
Current liabilities	$152.5M
Current ratio	1.69
Inventory turnover	2.07
Net working capital	$97.6M
Quick ratio	1.11
Working capital	$105.1M
Working capital turnover	5.98

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-5.97%
Dividend yield	0%
Shareholder yield	-5.97%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$11.64
1D price change	1.32%
1M price change	5.07%
1M total return	5.07%
1W price change	4.01%
1W total return	4.01%
1Y price change	116.24%
1Y return CAGR	116.36%
1Y total return	116.24%
20-day SMA	$13.74
200-day SMA	$10.84
3M price change	16.55%
3M total return	16.55%
3Y price change	341.03%
3Y return CAGR	63.97%
3Y total return	341.03%
50-day SMA	$13.72
50-day SMA vs 200-day SMA	50over200
52-week high	$15.89
52-week high date	2026-08-05
52-week low	$6.47
52-week low date	2025-11-21
5Y price change	-3.14%
5Y return CAGR	-0.64%
5Y total return	-3.14%
6M price change	44.96%
6M total return	44.96%
All-time high	$19.94
All-time high date	2021-06-28
All-time low	$0.80
All-time low date	2023-03-31
Average true range (ATR)	$0.52
Average volume	386.8K
Beta (1Y)	0.58
Beta (2Y)	0.54
Beta (5Y)	0.64
Change from 52-week high	-8.07%
Change from 52-week low	125.81%
Change from all-time high	-27.24%
Change from all-time low	1,713.98%
Change from open	1.32%
Day's gap	0%
Dollar volume	$7.4M
High price	$14.74
Low price	$14.42
Monthly RSI	69.91
Open price	$14.42
Position in 52-week range	59.37%
Premarket change	-1.04%
Premarket close	$14.42
Premarket price	$14.27
Previous close	$14.42
Price vs 150-day SMA	24.67%
Price vs 20-day SMA	5.62%
Price vs 200-day SMA	33.89%
Price vs 50-day SMA	5.77%
Relative volume	1.31
Return from IPO open	-3.97%
Return from IPO price	11.54%
RSI	58.57
Sharpe ratio	1.69
Sharpe ratio (3Y)	1.08
Sharpe ratio (5Y)	0.38
Sortino ratio	2.92
Sortino ratio (3Y)	1.96
Sortino ratio (5Y)	0.64
Volume	507.3K
Weekly RSI	64.76
YTD price change	95.03%
YTD total return	95.03%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	34.3M
Float percentage	40.79%
Shares change (QoQ)	1.19%
Shares change (YoY)	5.97%
Shares held by insiders	2.64%
Shares held by institutions	44.2%
Shares outstanding	84.1M
Short % of float	9.27%
Short % of shares	3.78%
Short ratio	6.3 days

Deeper analysis on BVS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BVS report

Is a complete BVS research report available?

No complete published report is available for Bioventus Inc. (BVS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Bioventus Inc. (BVS)

Price

Financial snapshot

Fair-value bridge

Latest news · BVS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BVS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BVS

Frequently asked questions